Article
Oncology
Rama Soundararajan, Paul Viscuse, Patrick Pilie, Jingjing Liu, Souzana Logotheti, Caddie Laberiano Fernandez, Daniele Lorenzini, Anh Hoang, Wei Lu, Luisa Maren Solis Soto, Ignacio I. Wistuba, Mingchu Xu, Xingzhi Song, Peter D. A. Shepherd, Nora M. Navone, Rebecca S. S. Tidwell, Guillermina Lozano, Christopher Logothetis, Jianhua Zhang, James P. Long, Marcos R. Estecio, Vasiliki Tzelepi, Ana M. Aparicio
Summary: Prostate cancer behaves differently in different patients, and understanding the molecular profiles of aggressive variants can inform targeted treatments. Alterations in the tumor suppressors TP53, RB1, and PTEN characterize the more virulent prostate cancers and predict their response to combination chemotherapies. Staining tumor tissues or examining their DNA can determine these molecular profiles.
Article
Biochemistry & Molecular Biology
Sankar Muthumanickam, Thangamariyappan Indhumathi, Pandi Boomi, Ramachandran Balajee, Jeyaraman Jeyakanthan, Krishnan Anand, Sundaram Ravikumar, Ponnuchamy Kumar, Arumugam Sudha, Zhihui Jiang
Summary: Prostate cancer is a major problem in men, and the existing chemotherapy drugs are not effective. Natural compounds like naringin, found in citrus fruits, may have potential as alternative therapeutic agents for prostate cancer.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2022)
Article
Oncology
Manqi Zhang, Yasemin Ceyhan, Shenglin Mei, Taghreed Hirz, David B. Sykes, Irina U. Agoulnik
Summary: Prostate cancer is driven by multiple genetic alterations, and the loss of INPP4B and PTEN is a common tumor suppressor loss in prostate cancer. The loss of INPP4B and PTEN triggers different compensatory responses in prostate tissue.
Article
Cell Biology
Yinjie Su, Bo Wang, Jian Huang, Ming Huang, Tianxin Lin
Summary: The study aimed to evaluate PTEN regulation and identify targets for relieving chemoresistance in bladder cancer. The expression of YTHDC1 was found to be associated with cisplatin sensitivity in patients with bladder cancer. Decreased YTHDC1 expression promotes cisplatin resistance, while overexpression of YTHDC1 enhances cisplatin sensitivity. Furthermore, reducing YTHDC1 expression activates DNA damage response, including faster cell cycle recovery, apoptosis evasion, and enhanced DNA repair capability.
CELL PROLIFERATION
(2023)
Article
Oncology
Carmela Ferri, Anna Di Biase, Marco Bocchetti, Silvia Zappavigna, Sarah Wagner, Pauline Le Vu, Amalia Luce, Alessia Maria Cossu, Jayakumar Vadakekolathu, Amanda Miles, David J. Boocock, Alex Robinson, Melanie Schwerdtfeger, Virginia Tirino, Federica Papaccio, Michele Caraglia, Tarik Regad, Vincenzo Desiderio
Summary: This study found that MALAT1 expression is associated with high Gleason grade, metastasis occurrence, and reduced survival in PCa patients. The study also revealed a direct interaction between miR-423-5p and MALAT1, which inhibits MALAT1's activity and suppresses cell proliferation, migration, and invasion in PCa.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Eddie Luidy Imada, Diego Fernando Sanchez, Wikum Dinalankara, Thiago Vidotto, Ericka M. Ebot, Svitlana Tyekucheva, Gloria Regina Franco, Lorelei Ann Mucci, Massimo Loda, Edward Matthew Schaeffer, Tamara Lotan, Luigi Marchionni
Summary: In this study, a transcriptional signature of PTEN loss in prostate cancer was identified, showing activation of immune systems and cell-cycle genes. The study also discovered potential novel lncRNAs associated with PTEN loss and prostate cancer progression, expanding the understanding of the molecular landscape in PCa. The findings suggest that PTEN loss in prostate cancer leads to increased immune system activation, contrary to observations in other cancers, which could have implications for the development of biomarkers and therapy choices.
Review
Oncology
Lucija Skara, Ana Hudek Turkovic, Ivan Pezelj, Alen Vrtaric, Nino Sincic, Bozo Kruslin, Monika Ulamec
Summary: Prostate cancer is closely associated with dysregulated cholesterol metabolism, and studies have revealed this connection. Cholesterol plays a significant role in prostate cancer, influencing cancer progression.
Article
Biochemistry & Molecular Biology
Tingting Feng, Ru Zhao, Hanwen Zhang, Feifei Sun, Jing Hu, Meng Wang, Mei Qi, Ling Liu, Lin Gao, Yabo Xiao, Junhui Zhen, Weiwen Chen, Lin Wang, Bo Han
Summary: This study reveals an inverse correlation between PTEN expression and unfolded protein response (UPR) signature score in prostate cancer. PTEN suppresses the activity of ATF6a by de-phosphorylating and inhibiting its nuclear translocation, while ATF6a promotes PTEN degradation through inducing CHIP expression. Inhibition of ATF6a in combination with AKT inhibitor shows promising anti-tumor effects. This study highlights ATF6a as a therapeutic target in PTEN dysfunctional prostate cancer.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2023)
Review
Oncology
Eduardo de Paula Nascente, Renee Laufer Amorim, Carlos Eduardo Fonseca-Alves, Veridiana Maria Brianezi Dignani de Moura
Summary: This study compares prostate cancer in humans and dogs, exploring the differences, similarities, and underlying mechanisms from the perspective of molecular and pathological biology. The research has significant implications for the diagnosis and treatment of this disease.
Review
Andrology
Shou-Yi Zhang, Yu Zeng
Summary: N-6-methyladenosine (m(6)A) is a common RNA modification in mammals that is involved in various aspects of RNA regulation. In prostate cancer, changes in m(6)A modification and its regulation have been extensively studied, revealing potential implications for cancer detection and treatment. This review summarizes the current understanding of m(6)A modification in prostate cancer and discusses its impact on cancer progression.
ASIAN JOURNAL OF ANDROLOGY
(2023)
Article
Endocrinology & Metabolism
Ross A. Vitek, Wei Huang, Peter G. Geiger, Erika Heninger, Joshua M. Lang, David F. Jarrard, David J. Beebe, Brian P. Johnson
Summary: In this study, methods were developed to enable molecular and functional analysis of prostate tumor microenvironment (TME) while maintaining compatibility with standard histopathology. By identifying suitable clinical cases and employing specific techniques, the study bridged clinical histopathology and TME interrogation, advancing our understanding of prostate cancer biology and potentially identifying new predictive and prognostic markers.
Article
Oncology
Rong Deng, Yanmin Guo, Lian Li, Jianfeng He, Zhe Qiang, Hailong Zhang, Ran Chen, Yanli Wang, Xian Zhao, Jianxiu Yu
Summary: The deubiquitinase BAP1 plays a critical role in stabilizing PTEN protein levels by inhibiting its degradation, thereby suppressing the AKT signaling pathway and inhibiting tumor progression in prostate cancer. Conversely, knockdown of BAP1 leads to the decrease in PTEN protein levels and activates the Akt signaling pathway, promoting malignant transformation and cancer metastasis. The positive correlation between BAP1 and PTEN levels in human cancers highlights the importance of the BAP1-PTEN signaling axis in tumor suppression.
MOLECULAR ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Vildan Bozok Cetintas, Zekeriya Duzgun, Taner Akalin, Erkin Ozgiray, Eda Dogan, Zafer Yildirim, Nevhis Akinturk, Huseyin Biceroglu, Yesim Ertan, Buket Kosova
Summary: This study investigated the stability, structural and functional effects, and pathogenicity of 12 missense PTEN mutations in glioblastoma patients. Computational tools and molecular dynamic simulation revealed deleterious effects, with some mutations showing significant protein stability decrease.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2022)
Article
Oncology
Feng He, Fenglin Zhang, Yi Liao, Moon-shong Tang, Xue-Ru Wu
Summary: Muscle-invasive bladder cancer (MIBC) exhibits strong inter- and intra-tumor heterogeneity and mutations in RTK-RAS-PI3K and P19-P53-P21 pathways are commonly observed. This study shows that deficiencies of both PTEN and P53 are responsible for driving the basal/squamous subtype MIBC. PTEN is inactivated by hyperphosphorylation of the C-terminus and this modification may serve as a biomarker for subtyping MIBC and predicting tumor progression. Tailless PTEN is a potential molecular therapeutic for accessible tumors like bladder cancer.
Article
Biochemistry & Molecular Biology
Yanmin Guo, Jianfeng He, Hailong Zhang, Ran Chen, Lian Li, Xiaojia Liu, Caihu Huang, Zhe Qiang, Zihan Zhou, Yanli Wang, Jian Huang, Xian Zhao, Junke Zheng, Guo-Qiang Chen, Jianxiu Yu
Summary: This study reveals the involvement of PTEN M1-ubiquitination in the regulation of AKT signaling and prostate cancer progression. The researchers identified specific ubiquitination sites on PTEN and showed that the M1-ubiquitination level correlates with clinical outcomes in prostate cancer patients. Additionally, they discovered that HOIP, a component of the LUBAC complex, plays a role in enhancing AKT signaling in a PTEN-dependent manner.
Article
Oncology
Violeta Serra, Anderson T. Wang, Marta Castroviejo-Bermejo, Urszula M. Polanska, Marta Palafox, Andrea Herencia-Ropero, Gemma N. Jones, Zhongwu Lai, Joshua Armenia, Filippos Michopoulos, Alba Llop-Guevara, Rachel Brough, Aditi Gulati, Stephen J. Pettitt, Krishna C. Bulusu, Jenni Nikkila, Zena Wilson, Adina Hughes, Paul W. G. Wijnhoven, Ambar Ahmed, Alejandra Bruna, Albert Gris-Oliver, Marta Guzman, Olga Rodriguez, Judit Grueso, Joaquin Arribas, Javier Cortes, Cristina Saura, Alan Lau, Susan Critchlow, Brian Dougherty, Carlos Caldas, Gordon B. Mills, J. Carl Barrett, Josep V. Forment, Elaine Cadogan, Christopher J. Lord, Cristina Cruz, Judith Balmana, Mark J. O'Connor
Summary: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance, providing new strategies for treating tumors such as breast and ovarian cancer.
CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Marco Sciacovelli, Aurelien Dugourd, Lorea Valcarcel Jimenez, Ming Yang, Efterpi Nikitopoulou, Ana S. H. Costa, Laura Tronci, Veronica Caraffini, Paulo Rodrigues, Christina Schmidt, Dylan Gerard Ryan, Timothy Young, Vincent R. Zecchini, Sabrina H. Rossi, Charlie Massie, Caroline Lohoff, Maria Masid, Vassily Hatzimanikatis, Christoph Kuppe, Alex Von Kriegsheim, Rafael Kramann, Vincent Gnanapragasam, Anne Y. Warren, Grant D. Stewart, Ayelet Erez, Sakari Vanharanta, Julio Saez-Rodriguez, Christian Frezza
Summary: Metabolic flexibility occurs during ccRCC progression, and the reprogramming of branched-chain amino acid catabolism and urea cycle allows for metabolic flexibility in renal cancer progression.
NATURE COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Ainara Cano, Mercedes Vazquez-Chantada, Javier Conde-Vancells, Aintzane Gonzalez-Lahera, David Mosen-Ansorena, Francisco J. J. Blanco, Karine Clement, Judith Aron-Wisnewsky, Albert Tran, Philippe Gual, Carmelo Garcia-Monzon, Joan Caballeria, Azucena Castro, Maria Luz Martinez-Chantar, Jose M. Mato, Huiping Zhu, Richard H. H. Finnell, Ana M. M. Aransay
Summary: Low serum folate levels are associated with metabolic associated fatty liver disease (MAFLD). The role of the folate transporter gene (SLC19A1) in lipid accumulation during the onset of MAFLD was assessed through genomic, transcriptomic, and metabolomic techniques. SNPs rs1051266 and rs3788200 were significantly associated with fatty liver development, and the lack of functional SLC19A1 affected gene regulation and lipid metabolism, leading to lipid droplet accumulation in hepatocytes.
Correction
Oncology
F. Guffanti, M. F. Alvisi, A. Anastasia, F. Ricci, M. Chiappa, A. Llop-Guevara, V. Serra, R. Fruscio, A. Degasperi, S. Nik-Zainal, M. R. Bani, M. Lupia, R. Giavazzi, E. Rulli, G. Damia
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Arkaitz Carracedo
Summary: The process of cellular transformation involves the acquisition of key features known as hallmarks of cancer, which are supported by molecular alterations and changes in the microenvironment. Cellular metabolism is a crucial link between a cell and its environment, and metabolic adaptation is an increasingly important research field in cancer biology.
MOLECULAR ONCOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Javier Plou, Pablo S. Valera, Isabel Garcia, David Vila-Liarte, Carlos Renero-Lecuna, Jesus Ruiz-Cabello, Arkaitz Carracedo, Luis M. Liz-Marzan
Summary: During the response to stress, damaged cells release metabolites and secretomes, which can be utilized in anticancer therapies and biomarker predictions. However, monitoring these processes is challenging, leading to the development of noninvasive secretome screening tools. Machine learning methods and microfluidic chips were used to identify secretome variations and classify cell death, allowing for faster implementation of surface-enhanced Raman scattering (SERS) into cell secretome classification.
Article
Cell Biology
Muireann Ni Bhaoighill, Juan M. Falcon-Perez, Felix Royo, Andrew R. Tee, Jason P. Webber, Elaine A. Dunlop
Summary: This study investigates the role of extracellular vesicles (EVs) in modulating the tumor microenvironment and their impact on the development of TSC tumors. It shows that EVs secreted from TSC2-deficient cells contain a specific protein cargo that promotes cell viability, proliferation, and growth factor secretion in the tumor microenvironment. The study also demonstrates that rapamycin can alter the cargo of EVs and reduce their ability to promote cell proliferation.
JOURNAL OF EXTRACELLULAR VESICLES
(2023)
Article
Microbiology
Felix Royo, Hector Tames, Guillermo Bordanaba-Florit, Diana Cabrera, Maria Azparren-Angulo, Clara Garcia-Vallicrosa, Abelardo Margolles, Lorena Ruiz, Patricia Ruas-Madiedo, Juan M. Falcon-Perez
Summary: This study used mice as a model and fed them with a bacterial strain of B. adolescentis that can degrade glutamate and convert it into GABA. The bacterium can survive in the gastric tract and the animals reduce their blood glutamate concentration over time. The results suggest that an oral diet with this probiotic-type bacteria could reduce the concentration of glutamate in the blood, providing a reference for clinical trial studies in patients with chronic diseases.
MICROBIOLOGY SPECTRUM
(2023)
Review
Biochemistry & Molecular Biology
Clara Garcia-Vallicrosa, Juan M. Falcon-Perez, Felix Royo
Summary: The human CERS2 gene encodes a protein called CERS2, which has been found to have antitumor effects in various types of cancer, but promotes tumor growth in adenocarcinoma. This review focuses on the influence of CERS2 in bladder cancer, including its structure, activity, and the miRNAs that regulate its expression. Mechanistically, CERS2 may act as an antitumor protein through the production of long-chain ceramides, interaction with vacuolar ATPase, and inhibition of mitochondrial fission. Additionally, the expression of CERS2 in bladder cancer and its association with disease progression are discussed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Jan Pencik, Cecile Philippe, Michaela Schlederer, Emine Atas, Matteo Pecoraro, Sandra Grund-Groeschke, Wen (Jess) Li, Amanda Tracz, Isabel Heidegger, Sabine Lagger, Karolina Trachtova, Monika Oberhuber, Ellen Heitzer, Osman Aksoy, Heidi A. Neubauer, Bettina Wingelhofer, Anna Orlova, Nadine Witzeneder, Thomas Dillinger, Elisa Redl, Georg Greiner, David D'Andrea, Johnny R. Ostman, Simone Tangermann, Ivana Hermanova, Georg Schaefer, Felix Sternberg, Elena E. Pohl, Christina Sternberg, Adam Varady, Jaqueline Horvath, Dagmar Stoiber, Tim I. Malcolm, Suzanne D. Turner, Eileen E. Parkes, Brigitte Hantusch, Gerda Egger, Stefan Rose-John, Valeria Poli, Suneil Jain, Chris W. D. Armstrong, Gregor Hoermann, Vincent Goffin, Fritz Aberger, Richard Moriggl, Arkaitz Carracedo, Cathal McKinney, Richard D. Kennedy, Helmut Klocker, Michael R. Speicher, Dean G. Tang, Ali A. Moazzami, David M. Heery, Marcus Hacker, Lukas Kenner
Summary: PTEN and STAT3 are frequently co-deleted genes in metastatic prostate cancer (mPCa). STAT3 controls mPCa through the LKB1/pAMPK/mTORC1/CREB signaling pathway, and metformin can inhibit mPCa growth.
Article
Biochemistry & Molecular Biology
Raquel Garcia-Vilchez, Ana M. M. Anazco-Guenkova, Sabine Dietmann, Judith Lopez, Virginia Moron-Calvente, Silvia D'Ambrosi, Paz Nombela, Kepa Zamacola, Isabel Mendizabal, Saioa Garcia-Longarte, Amaia Zabala-Letona, Ianire Astobiza, Sonia Fernandez, Alejandro Paniagua, Borja Miguel-Lopez, Virginie Marchand, Diego Alonso-Lopez, Angelika Merkel, Ignacio Garcia-Tunon, Aitziber Ugalde-Olano, Ana Loizaga-Iriarte, Isabel Lacasa-Viscasillas, Miguel Unda, Mikel Azkargorta, Felix Elortza, Laura Barcena, Monika Gonzalez-Lopez, Ana M. M. Aransay, Tomas Di Domenico, Manuel A. A. Sanchez-Martin, Javier De Las Rivas, Sonia Guil, Yuri Motorin, Mark Helm, Pier Paolo Pandolfi, Arkaitz Carracedo, Sandra Blanco
Summary: New evidence suggests that epitranscriptomic marks play an important role in cancer development, but the role and implications of altered epitranscriptome deposition in prostate cancer are largely unknown. This study demonstrates that the transfer RNA N-7-methylguanosine (m(7)G) transferase METTL1 is highly expressed in prostate tumors and its depletion leads to the loss of m(7)G tRNA methylation and the formation of small non-coding RNAs derived from 5'tRNA fragments. These small RNAs regulate translation control and favor the synthesis of key regulators and immune effectors, impacting tumor growth suppression and response to immunotherapy in prostate cancer models.
Article
Cell Biology
Connor Rogerson, Marco Sciacovelli, Lucas A. Maddalena, Andromachi Pouikli, Marc Segarra-Mondejar, Lorea Valcarcel-Jimenez, Christina Schmidt, Ming Yang, Elena Ivanova, Joshua Kent, Ariane Mora, Danya Cheeseman, Jason S. Carroll, Gavin Kelsey, Christian Frezza
Summary: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a cancer syndrome caused by inactivating germ-line mutations in fumarate hydratase (FH) and subsequent accumulation of fumarate. Fumarate accumulation leads to profound epigenetic changes and the activation of an antioxidant response via nuclear translocation of the transcription factor NRF2. The identification of FOXA2 as an antioxidant regulator provides additional insights into the molecular mechanisms behind cell responses to fumarate accumulation and potentially provides further avenues for therapeutic intervention for HLRCC.
Review
Oncology
Nadia Saoudi Gonzalez, Francesc Salva, Javier Ros, Iosune Baraibar, Marta Rodriguez-Castells, Ariadna Garcia, Adriana Alcaraz, Sharela Vega, Sergio Bueno, Josep Tabernero, Elena Elez
Summary: Metastatic colorectal cancer is a complex and life-threatening disease influenced by various factors. Tumor heterogeneity, caused by genetic and non-genetic factors, affects tumor development and therapy effectiveness. Computational analysis of next-generation sequencing and real-time monitoring of circulating tumor DNA are valuable tools in understanding tumor evolution and heterogeneity.
Article
Medicine, Research & Experimental
Ana Garcia-del Rio, Endika Prieto-Fernandez, Leire Egia-Mendikute, Asier Antonana-Vildosola, Borja Jimenez-Lasheras, So Young Lee, Adrian Barreira-Manrique, Samanta Romina Zanetti, Ander de Blas, Paloma Velasco-Beltran, Alexandre Bosch, Ana M. Aransay, Asis Palazon
Summary: Factor-inhibiting HIF (FIH) is an asparagine hydroxylase expressed in tumors, and its deletion may lead to increased metabolism, decreased proliferation, and increased immune infiltration in cancer cells.
Meeting Abstract
Gastroenterology & Hepatology
Maider Apodaka-Biguri, Francisco Gonzalez-Romero, Andre L. Simao, Daniela Mestre Congregado, Igor Aurrekoetxea, Beatriz Gomez Santos, Igotz Delgado, Xabier Buque, Ane Nieva-Zuluaga, Mikel Ruiz de Gauna, Idoia Fernandez-Puertas, Ainhoa Iglesias, Ana Maria Aransay, Juanjo Lozano, Cesar Augusto Martin, Irantzu Bernales, Pedro Miguel Rodrigues, Jesus Maria Banales, Ana Zubiaga, Rui E. Castro, Patricia Aspichueta
JOURNAL OF HEPATOLOGY
(2023)